Ocular Therapeutix, Inc. — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016. This is an annual report, not a standalone Q4 filing; the filing also reports unaudited fourth-quarter results. Ocular Therapeutix is a development-stage ophthalmology company using a bioresorbable hydrogel platform. ReSure Sealant was its only marketed product; DEXTENZA and OTX-TP were its leading clinical candidates.
Financial results and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Total revenue | $1.887 million | $1.750 million |
| Product revenue | $1.845 million | $1.354 million |
| Collaboration revenue | $42,000 | $396,000 |
| Operating expenses | $45.213 million | $39.947 million |
| Loss from operations | $43.326 million | $38.197 million |
| Net loss | $44.703 million | $39.748 million |
| Net loss per share | $1.80 | $1.71 |
| Cash used in operating activities | $34.001 million | $33.743 million |
- Product revenue was from ReSure Sealant. Cost of product revenue was $443,000, implying calculated product gross profit of about $1.402 million and a gross margin of about 76% on product revenue; this excludes other operating expenses.
- R&D expense was $27.065 million, selling and marketing $6.701 million, and general and administrative expense $11.004 million. Total operating expenses rose 13% year over year, while net loss widened by $4.955 million.
- Cash, cash equivalents and marketable securities totaled $68.145 million at year-end, down from $105.064 million. Working capital was $61.598 million; total assets were $74.939 million and stockholders’ equity was $52.008 million.
- Year-end notes payable, net of discount, were $15.643 million, including $1.549 million current. The existing facility carried an 8.25% stated rate. Interest expense was $1.680 million.
- Management estimated year-end resources would fund operations, debt service and capital spending into Q2 2018, based on then-current plans and assumptions. The filing says additional financing would be needed for a potential DEXTENZA launch.
- FY 2016 quarterly data show Q4 revenue of $511,000 and net loss of $12.822 million, versus Q4 2015 revenue of $436,000 and net loss of $10.637 million.
Material changes and business developments
- Revenue increased $137,000 overall as ReSure sales grew, but collaboration revenue fell $354,000. Net loss increased $4.955 million; higher selling and marketing, G&A and unallocated R&D costs outweighed the revenue increase.
- DEXTENZA: The FDA issued a Complete Response Letter in July 2016 because of manufacturing process and control deficiencies, not identified clinical efficacy or safety concerns. The company resubmitted the NDA in January 2017; the FDA accepted it for a major review with a July 19, 2017 target action date. A manufacturing re-inspection might still be required.
- DEXTENZA’s third Phase 3 post-surgical trial met both primary endpoints; one of the two earlier Phase 3 trials did not meet its inflammation endpoint. In allergic conjunctivitis, one Phase 3 trial met the itching endpoint but not redness; the second missed its sole itching endpoint.
- OTX-TP entered Phase 3 testing in September 2016. Its Phase 2b trial showed less IOP reduction than the timolol comparator on reported measures; the pivotal trials use a different, placebo-insert design.
- The company entered a Regeneron collaboration in October 2016 for a hydrogel depot with large-molecule VEGF-targeting drugs, initially aflibercept. Regeneron had not exercised its option and no payments had been made by year-end. Potential option, milestone and royalty payments are contingent; the company could have to reimburse eligible development costs up to $25 million, potentially increased by $5 million.
- ReSure Sealant sales remained limited. The company terminated independent distributors and moved to a four-person contract sales force in early 2017; it did not expect meaningful ReSure revenue in 2017.
Outlook, risks and unusual items
- Management estimated 2017 R&D expense of $33–$35 million, including approximately $17–$19 million of external clinical-trial and regulatory costs. It expected $12–$15 million of external expense for OTX-TP and $2.0–$2.8 million for DEXTENZA post-surgical inflammation and pain.
- Subject to FDA approval, the company expected a U.S. DEXTENZA launch in Q1 2018. It anticipated using a contract sales organization and expected to need additional financing. Launch timing and reimbursement remain uncertain; CMS pass-through and J-code applications do not assure coverage or payment.
- The company reported a $1.263 million write-off of manufacturing equipment under construction in 2016, reflected in the cash-flow reconciliation as a loss on disposal of property and equipment. It also entered a lease for a new approximately 71,000-square-foot facility, with substantial build-out and equipment spending planned.
- Subsequent events: a January 2017 stock offering produced approximately $23.5 million net proceeds. In March 2017, the credit facility was amended to a $38 million total commitment, including $18 million drawn at closing and two conditional $10 million tranches. These are post-year-end developments, not year-end cash or debt balances.
- Key risks include ongoing operating losses and financing needs; regulatory and manufacturing uncertainty; clinical-trial outcomes and insert retention; competition and generic alternatives; reimbursement and market adoption; reliance on suppliers, including a sole-source PEG supplier; and dependence on Incept-licensed intellectual property. Management reported effective disclosure controls and internal control over financial reporting. No material legal proceedings were reported.
Investor verification priorities
- Check the FDA’s July 2017 action on DEXTENZA and whether manufacturing deficiencies or inspection findings remain unresolved.
- Track OTX-TP Phase 3 enrollment, retention, safety and efficacy results, particularly versus the placebo-insert design.
- Reconcile cash runway and financing needs using subsequent offering proceeds, actual operating cash burn, facility costs and the March 2017 debt amendment and conditions.
- Verify ReSure commercial traction and DEXTENZA reimbursement, pricing and launch assumptions if approved.
- Review the Regeneron option status, development-cost obligations and whether any contingent milestones or royalties become probable or payable.